Scientists advance a new explanation for how Aβ dampens synaptic plasticity.
Researchers argue for a public-private superfund to advance many Alzheimer’s therapeutics projects in parallel.
Passive immunotherapy shows moderate success in a mouse model of sporadic Parkinson’s disease.
Levodopa may have a slight edge over newer treatments for Parkinson’s disease.
A new interface allows researchers to mix and match data from genome-wide association studies in search of genes involved in sporadic amyotrophic lateral sclerosis.
A novel mutation frays mitochondrial DNA and impedes ATP synthesis in people with an ALS-FTD-like syndrome.
Several thousand people have used preimplantation genetic diagnosis to avoid passing on pathogenic mutations to their babies, but many families with a history of Alzheimer’s or related diseases remain unaware of this option.
Families considering PGD to avoid passing on disease genes face obstacles such as high cost and invasive procedures.
Researchers retract two papers that claimed a quick dunk in acid turns mature mouse lymphocytes into pluripotent cells.
An award-winning film follows a social worker set on bringing music to people with dementia, and documents their unforgettable moments of awakening.
Antipsychotic medications repurposed to accelerate autophagy might prevent cellular toxicity associated with mutant TDP-43.
In fruit flies that model ALS, presynaptic vesicles gather in unusually large clumps, amplifying signaling at the neuromuscular junction. Does this promote disease?
Novartis Pharmaceuticals Corporation will partner with the Banner Alzheimer's Institute testing experimental preclinical therapies in the upcoming Alzheimer's Prevention Initiative ApoE4 study. The study complements the API ADAD trial.
The enzyme PARC acts as a survival factor in damaged neurons and cancer cells by targeting a pro-apoptotic protein for destruction.
Could tweaking methodologies improve amyloid diagnosis and tracking?